Table 3 Linear regression Models for metabolic factors in PD. B(95%CI) and p values are presented for measures found significant in the model.

From: Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson’s disease

 

Number of metabolic factors

Prediabetes

Hypertension

hypertriglyceridemia

Low HDL

Obesity

Model

F = 4.928; p < 0.0001

F = 4.068; p < 0.0001

F = 2.121; p = 0.026

F = 3.664; p < 0.0001

F = 0.838; p = 0.593

F = 1.299; p = 0.236

Genotype

0.21(0.03–0.39); 0.02*

0.095(0.009–0.180); 0.031*

0.08(0.008–0.165); 0.032^

   

Sex

  

−0.14(−0.281–0); 0.051

   

Age

0.46(0.03–0.06); 0.0001

0.022(0.014–0.030); 0.0001

0.011(0.003–0.018); 0.004

0.018(0.010–0.026); 0.0001

  

Disease duration

−0.82(−0.16–0.002); 0.055

     

RBDQ

   

0.029(0.002–0.057); 0.037

  

LEDD

      

UPDRS-III

      

MOCA

      

UPSIT

      

NMSQ

      
  1. *- significance driven by iPD; ^- significance driven by LRRK2-PD.
  2. RBDQ- REM sleep Behavior Disorder Questionnaire, LEDD- LevoDopa Equivalent Daily Dose, UPDRS- Unified Parkinson’s Disease Rating Scale part III, MoCA – Montreal Cognitive Assessment, UPSIT- University of Pennsylvania Smell Identification Test, NMSQ- Non-Motor Symptoms questionnaire.
Back to article page